Literature DB >> 7478595

Regulation of E2F-1 gene expression by p130 (Rb2) and D-type cyclin kinase activity.

D G Johnson1.   

Abstract

Previous experiments have demonstrated that the regulation of E2F-1 transcription factor activity is critical for the maintenance of normal cell proliferation control. Regulation of E2F-1 is accomplished through at least two mechanisms: posttranslational regulation by binding proteins such as Rb and transcriptional regulation of the E2F-1 gene. The E2F-1 gene promoter has recently been isolated to examine this latter aspect of E2F-1 regulation. Preliminary studies demonstrate that the E2F-1 promoter is under E2F-dependent negative control during the cell growth response, being transcriptionally repressed through E2F sites in G0 and early G1. We now demonstrate that the presence of an E2F DNA-binding complex containing the Rb-related p130 protein (Rb2) correlates with E2F-1 gene repression and that overexpression of p130 inhibits transcription from the E2F-1 promoter. Moreover, D-type cyclin-dependent kinase activity specifically activates the E2F-1 promoter by relieving E2F-mediated repression but is inhibited by coexpression of the cdk4 and cdk6 inhibitor p16 (CDKN2, MTS1, INK4). Taken together, these findings suggest that E2F-1 gene expression is controlled during cell cycle progression by a regulatory network involving at least one oncogene (cyclin D1) and several potential tumor suppressor genes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7478595

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  16 in total

1.  E2F is required to prevent inappropriate S-phase entry of mammalian cells.

Authors:  S He; B L Cook; B E Deverman; U Weihe; F Zhang; V Prachand; J Zheng; S J Weintraub
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

2.  Constitutive E2F1 overexpression delays endochondral bone formation by inhibiting chondrocyte differentiation.

Authors:  Blanca Scheijen; Marieke Bronk; Tiffany van der Meer; René Bernards
Journal:  Mol Cell Biol       Date:  2003-05       Impact factor: 4.272

Review 3.  Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC).

Authors:  Courtney Pollard; Steven C Smith; Dan Theodorescu
Journal:  Expert Rev Mol Med       Date:  2010-03-25       Impact factor: 5.600

4.  Transcriptional upregulation of p57 (Kip2) by the cyclin-dependent kinase inhibitor BMS-387032 is E2F dependent and serves as a negative feedback loop limiting cytotoxicity.

Authors:  Y Ma; W D Cress
Journal:  Oncogene       Date:  2006-12-18       Impact factor: 9.867

5.  Differential regulation of the retinoblastoma family of proteins during cell proliferation and differentiation.

Authors:  J Garriga; A Limón; X Mayol; S G Rane; J H Albrecht; E P Reddy; V Andrés; X Graña
Journal:  Biochem J       Date:  1998-08-01       Impact factor: 3.857

6.  p130 is dispensable in peripheral T lymphocytes: evidence for functional compensation by p107 and pRB.

Authors:  G J Mulligan; J Wong; T Jacks
Journal:  Mol Cell Biol       Date:  1998-01       Impact factor: 4.272

7.  Distinct roles for E2F proteins in cell growth control and apoptosis.

Authors:  J DeGregori; G Leone; A Miron; L Jakoi; J R Nevins
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

8.  The accumulation of an E2F-p130 transcriptional repressor distinguishes a G0 cell state from a G1 cell state.

Authors:  E J Smith; G Leone; J DeGregori; L Jakoi; J R Nevins
Journal:  Mol Cell Biol       Date:  1996-12       Impact factor: 4.272

9.  Phosphorylation-dependent and -independent functions of p130 cooperate to evoke a sustained G1 block.

Authors:  K Hansen; T Farkas; J Lukas; K Holm; L Rönnstrand; J Bartek
Journal:  EMBO J       Date:  2001-02-01       Impact factor: 11.598

10.  Transcriptional activation by the Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen is facilitated by an N-terminal chromatin-binding motif.

Authors:  Lai-Yee Wong; Gerald A Matchett; Angus C Wilson
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.